Optimizing Oncology And Rare Disease Clinical Trials By Focusing On Science And Aligning With Both Patients And Investigators

By Dave Selkirk, President, Clinical Research

Ergomed, a mid-sized, full-service contract research organization (CRO), has built a strong reputation over 25 years through its specialized focus on oncology and rare disease clinical research. The company’s roots in co-development have instilled a deep commitment to scientific partnership and outcome-driven research. Ergomed distinguishes itself through a consultative, data-informed, and patient-centric approach, supported by a team rich in medical and scientific expertise.

Embracing digital and decentralized trial models, Ergomed prioritizes hybrid designs that balance in-person and remote elements—crucial for rare diseases and oncology populations. Its global footprint ensures sensitivity to regional regulatory and cultural contexts, while specialized teams engage directly with patients, clinicians, and data to optimize trial design and execution. With growing geographic expansion into Asia and a forward-looking embrace of wearable tech, real-world data, and AI, Ergomed is positioning itself as a dynamic leader in the evolving clinical research landscape.